Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
SOUTH SAN FRANCISCO - Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company with a market capitalization of $318 million, has released interim data from its Phase 1 clinical trial for soquelitinib, a drug being tested for the treatment of moderate to severe atopic dermatitis. The company’s stock has shown strong momentum, delivering a 91% return over the past year according to InvestingPro data. The data indicates that cohort 3, which received a higher dose of the medication, showed a more significant improvement in symptoms compared to earlier cohorts and placebo.
The trial, which is randomized, double-blind, and placebo-controlled, has completed enrollment for all three cohorts, with a total of 48 patients. Cohort 3 patients, treated with 200 mg of soquelitinib twice daily, exhibited a 64.8% reduction in the Eczema Area and Severity Index (EASI) score at day 28, compared to a 54.6% reduction in cohorts 1 and 2 and a 34.4% reduction in the placebo group. The company maintains a strong financial position, with InvestingPro analysis showing more cash than debt on its balance sheet and liquid assets exceeding short-term obligations.
Additionally, 50% of patients in cohort 3 experienced a clinically meaningful reduction in itch by day 8, a significant symptom of atopic dermatitis. Safety data up to May 28, 2025, suggests that soquelitinib is well-tolerated, with no dose-limiting toxicities or significant lab abnormalities across all cohorts.
Corvus has also initiated an extension cohort study to explore the effects of the same 200 mg twice daily dose over an 8-week treatment period, extending beyond the initial 4-week period studied in cohorts 1-3.
The company’s CEO, Dr. Richard A. Miller, expressed optimism about the potential of soquelitinib as a treatment for atopic dermatitis and other immune diseases. The new data will be presented at the Jefferies Global Healthcare Conference. Analysts share this optimism, with price targets ranging from $11 to $24 per share, though InvestingPro subscribers can access 11 additional key insights about CRVS’s financial health and market position through the comprehensive Pro Research Report, available exclusively on the platform.
Soquelitinib is part of Corvus Pharmaceuticals’ broader effort to develop ITK inhibition as an immunotherapy approach for cancer and immune diseases. The company emphasizes that the positive results are supportive of soquelitinib’s potential as a convenient treatment option for patients with atopic dermatitis.
This article is based on a press release statement from Corvus Pharmaceuticals.
In other recent news, Corvus Pharmaceuticals reported its first-quarter 2025 earnings with a slight miss, posting an EPS of -0.13 against a forecast of -0.12. Despite this, the company saw a significant stock surge, reflecting investor optimism due to promising trial results for its drug soquelitinib in atopic dermatitis. The company’s financial position improved with a net income of $15.2 million, a turnaround from a net loss of $5.7 million in the same period last year. This improvement was partly attributed to increased financial inflows from a warrant exercise.
Mizuho Securities recently adjusted its price target for Corvus Pharmaceuticals from $12.00 to $11.00, maintaining an Outperform rating, citing optimism about soquelitinib’s profile based on early-stage data. Oppenheimer analyst Jeff Jones also maintained an Outperform rating, raising the price target from $2 to $17, highlighting the promising clinical-stage programs. Corvus Pharmaceuticals’ recent trial results showed that soquelitinib demonstrated a favorable safety and efficacy profile, particularly at a 200 mg dosage, leading the company to plan further trials.
The company is preparing to initiate a Phase 2 trial for soquelitinib in atopic dermatitis before the end of the year, with plans to explore potential expansion into other immune diseases. These developments indicate a strong focus on advancing their clinical trials and expanding their therapeutic indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.